SPECTRACEF

Compare SPECTRACEF  to:
Compare
Compare

Generic Name for SPECTRACEF

Cefditoren (as pivoxil) 200mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SPECTRACEF

Cephalosporin.

Manufacturer of SPECTRACEF

Cornerstone Therapeutics, Inc.

Indications for SPECTRACEF

Susceptible mild to moderate acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections.

Adult dose for SPECTRACEF

Take with meals. Bronchitis: 400mg twice daily for 10 days. Pneumonia: 400mg twice daily for 14 days. Pharyngitis/tonsillitis, skin and skin structure: 200mg twice daily for 10 days. Renal impairment (CrCl 30–49mL/min): max 200mg twice daily; CrCl <30mL/min: max 200mg once daily; ESRD: contact manufacturer.

Children's dosing for SPECTRACEF

Not recommended.

Contraindications for SPECTRACEF

Milk protein allergy (not lactose intolerance). Carnitine deficiency or conditions causing carnitine deficiency.

Precautions for SPECTRACEF

Penicillin or other allergy. Not for long-term therapy. Decreased muscle mass (risk of carnitine deficiency). Monitor prothrombin time in renal or hepatic impairment or poor nutritional state. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for SPECTRACEF

Avoid drugs that reduce gastric acidity. Potentiated by probenecid. May cause false (+) glucose test with Clinitest, Fehling's or Benedict's soln, Coomb's test; false (–) with ferricyanide test.

Adverse Reactions for SPECTRACEF

GI upset, headache, transient reduction in plasma carnitine levels.

How is SPECTRACEF supplied?

Tabs—60

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives
Pneumonia

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.